Letrozole as primary therapy for endometrial hyperplasia in young women.
OBJECTIVE
To study letrozole as a primary therapeutic agent for endometrial hyperplasia with or without atypia in young women.


METHODS
Five premenopausal women presenting for infertility were diagnosed as having endometrial hyperplasia. A second biopsy was performed after they were treated for 3 months with 2.5 mg of letrozole per day. Serum levels of estradiol and progesterone were measured each month.


RESULTS
Curettage of the endometrium at the end of treatment revealed no evidence of endometrial hyperplasia or atypia in any of the patients. Low serum levels of estradiol were found in all patients.


CONCLUSIONS
This case series indicates that aromatase inhibitors deserve attention for the conservative treatment of endometrial hyperplasia. However, more studies are needed to confirm the efficacy and safety of this agent.
Li
H Z
HZ
Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University, Third HospitalBeijing, China.
Chen
X N
XN
Qiao
J
J
D000328:Adult; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D004714:Endometrial Hyperplasia / Q000188:drug therapy*; D004717:Endometrium / Q000187:drug effects* / Q000473:pathology; D005260:Female; D006801:Humans; D000077289:Letrozole; D009570:Nitriles / Q000627:therapeutic use; D010865:Pilot Projects; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use
D047072:Aromatase Inhibitors; D009570:Nitriles; D014230:Triazoles; D000077289:Letrozole